Keywords
chronic systemic inflammation
insulin resistance
metabolic disorders
How to Cite
Abstract
A review of the literature on the metabolic role of visceral adipose tissue and the main methods for its diagnosis is presented. Visceral adipose tissue is an active endocrine organ what secretes a number of biologically active substances. With an increase in the proportion of visceral adipose tissue, moderate inflammation is observed with a chronic systemic increase in the activity of adipokines. Adipokines carry out several immune or metabolic functions associated with inflammatory infiltration. Active substances such as leptin, adiponectin, resistin, etc., the source of which is visceral adipose tissue, have peripheral, central and local effects on the metabolism of glucose and lipids, glycolysis processes in the liver, etc. It is the activity of visceral adipose tissue that should be considered among the main pathophysiological development factors obesity and its potential metabolic cardiovascular and/or liver complications.
References
Galic S., Oakhill J.S., Steinberg G.R. (2010). Adipose tissue as an endocrine organ. Mol. Cell. Endocrinol., vol. 316, pp. 129–139.
Abraham T.M., Pedley A., Massaro J.M., Hoffmann U., Fox C.S. (2015). Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors. Circulation, vol. 132 (17), pp. 1639–1647.
Ahonen T.M., Saltevo J.T., Kautiainen H.J., Kumpusalo E.A., Vanhala M.J. (2012). The association of adiponectin and low-grade inflammation with the course of metabolic syndrome. Nutr. Metab. Cardiovasc. Dis., vol. 22, pp. 285–291.
Amato M.C., Giordano C., Galia M., Criscimanna A., Vitabile S., Midiri M. et al. (2010). Visceral adiposity index. A reliable indicator of visceral fat function associated with cardiometabolic risk. Diab. Care, vol. 33 (4), pp. 920–922.
Rodriguez-Hernandez H., Simental-Mendia L.E., Rodriguez-Ramirez G., Reyes-Romero M.A. (2013). Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int. J. Endocrinol., vol. 3, pp. 1–11.
Berner L.A., Arigo D., Mayer L.E., Sarwer D.B., Lowe M.R. (2015). Examination of central body fat deposition as a risk factor for loss-of-control eating. The American Journal of Clinical Nutrition, vol. 102 (4), pp. 736.
Chen S.H., Hе F., Zhou H.L., Wu H.R., Xia C., Li Y.M. (2011). Relationship between nonalcoholic fatty liver disease and metabolic syndrome. J. Digestive Diseases, vol. 12, pp. 125–130.
European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. (2016). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obesity Facts, vol. 9, № 2, pp. 65–90.
Gariani К., Jornayvaz F. (2013). Non-alcoholic fatty liver disease and insulin resistance: From bench to bedside. Diabetes & Metabolism, vol. 16, pp. 130–137.
Jung U.J., Choi M.S. (2014). Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Іnt. J. Mol. Sci., vol. 15 (4), pp. 6184–6223.
Musso G. (2012). Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatol., vol. 56 (3), pp. 933–942.